摘要
目的探讨血清尾加压素Ⅱ(UⅡ)在慢性肝炎、肝纤维化、肝硬化病程发展中的变化及临床应用价值。方法酶联免疫吸附实验(ELISA)测定40例慢性乙型肝炎、47例肝纤维化、38例肝硬化和30例健康对照者血清中的UⅡ水平。自动分析仪检测血清天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、总胆红素(TBIL)浓度。聚合酶链反应(PCR)诊断系统检测乙型肝炎病毒基因(HBV-DNA)。各患者组与健康对照组之间的比对采用方差分析。结果与健康对照组相比,血清UⅡ水平在各组患者中均表达升高(P<0.05),其中UⅡ水平在肝纤维化组升高高于慢乙型肝炎组(P<0.05),肝硬化组高于肝纤维化组(P<0.05)。血清UⅡ水平与透明质酸(HA)、Ⅳ型胶原蛋白(C-Ⅳ)、层黏蛋白(LN)、AST、ALT水平呈正相关性(r=0.784、0.473、0.355、0.776、0.653,P=0.017、0.026、0.035、0.012、P<0.01)。血清UⅡ水平与HBV-DNA复制水平呈正相关性(r=0.571,P=0.023)。结论血清UⅡ水平在慢性HBV相关性肝病,尤其是乙型肝炎肝纤维化中表达明显升高,UⅡ检测对协助诊断及监测早期肝纤维化具有积极的临床意义。
Objective To explore the expression and significance of serum urotensinⅡ（UⅡ）in patients with chronic hepatitis B（CHB）,liver fibrosis and liver cirrhosis.Methods Serum levels of UⅡ,hyaluronic acid（HA）,laminin（LN）,type Ⅳ collagen（C-Ⅳ）,aspartate aminotransferase（AST）,alanine aminotransferase（ALT）and HBV-DNA were detected in 40cases with CHB,47cases with liver fibrosis,38cases with liver cirrhosis and 30 healthy subjects,and all data were statistically compared.Results Compared with health control group,serum UⅡ levels in the three patient groups were all increased（P0.05）.There was an increasing tendency of serum UⅡlevel from CHB to liver cirrhosis（P0.05）.Serum level of UⅡ was positively correlated with HA,C-Ⅳ,LN,AST,ALT and HBV-DNA（r=0.784,0.473,0.355,0.776,0.653,0.571,P0.05）.Conclusion Serum level of UⅡ could be increased in CHB patients especially in patients with liver fibrosis,which might be with clinical significance in the diagnosis and monitoring of early liver fibrosis.
出处
《检验医学与临床》
CAS
2013年第18期2359-2360,2362,共3页
Laboratory Medicine and Clinic
